The Institute of Pharmaceutical Research of Harbin Pharmaceutical Group was established in March 2011. Its predecessor was the Harbin Pharmaceutical Industry Research Institute founded in 1991. It is among the first batch of state-level enterprise technology centers and is affiliated with Harbin Pharmaceutical Group Co., Ltd. The Institute focuses on the research and development of innovative drugs and high-tech products, while also working to enhance industrial technology, with the aim of strengthening the core competitiveness of Harbin Pharmaceutical Group. It has completed over 90 major national, provincial, and municipal research projects, achieved more than 90 scientific research results, obtained nearly 140 new drug certificates, received over 110 awards at international and domestic levels, and secured 89 authorized patents, with over 90% of its scientific achievements successfully industrialized. The Institute currently employs 2 postdoctoral researchers, 10 Ph.D. holders, over 50 master's degree holders, and more than 100 scientific researchers, forming a well-structured, experienced, dynamic, and highly capable research team.

For many years, Shenyang DASAN Pharmaceutical Technology Co., Ltd. has specialized in technology development and transfer for chemical drugs, APIs, and health foods, as well as regulatory consulting services. Since the nationwide implementation of the Marketing Authorization Holder (MAH) system, the company has been committed to building an MAH holder and transformation platform, focusing on the practical application of "MAH platform + projects + technological innovation and transfer." It has achieved notable results in technology R&D, MAH product transformation, product development driven by R&D, sales, and various forms of cooperation.